{
  "source": "PA-Med-Nec-Endari.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2135-9\nProgram Prior Authorization/Medical Necessity\nMedications Endari® (L-glutamine Powder for Solution)\nP&T Approval Date 11/2017, 2/2018, 2/2019, 2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nEndari (L-glutamine powder for solution) is indicated to reduce the acute complications of\nsickle cell disease in adult and pediatric patients 5 years of age and older. The recommended\ndose is 5 to 15 grams orally twice daily based on body weight.\n2. Coverage Criteriaa:\nA. Endari\n1. Initial Authorization\na. Endari will be approved based on the following criteria:\n1) Both of the following:\na) Diagnosis of sickle cell disease\nb) Used to reduce acute complications of sickle cell disease\n- AND –\n2) One of the following:\na) Patient is using Endari with concurrent hydroxyurea therapy\nb) Patient is unable to take hydroxyurea due to a contraindication or intolerance\n- AND –\n3) Patient has had 2 or more painful sickle cell crises within the past 12 months\n- AND –\n4) History of failure to non-prescription L-glutamine supplementation.\nAuthorization will be issued for 12 months.\n2. Reauthorization\n1. Endari will be approved based on the following criterion:\na. Documentation of positive clinical response to Endari therapy\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply Limits may be in place\n4. References:\n1. En",
    "story, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply Limits may be in place\n4. References:\n1. Endari [package insert]. Torrance, CA: Emmaus Medical, Inc.; October 2020.\n2. FDA Center For Drug Evaluation and Research Clinical review. Endari. June 7, 2017.\n2208587Orig1s000MedR.pdf (fda.gov).\nProgram Prior Authorization/Medical Necessity – Endari® (L-glutamine Powder for\nSolution)\nChange Control\n11/2017 New program.\n2/2018 Added requirement for L-glutamine supplementation.\n2/2019 Annual review with no changes.\n2/2020 Annual review with no changes.\n2/2021 Annual review. Updated references.\n2/2022 Annual review with no changes.\n2/2023 Annual review. Updated references.\n2/2024 Annual review. No changes.\n2/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}